Facial Skin Aging: What New Research Shows

Key Takeaways

• A 2025 multimodal ultrasound study found that facial skin thickness and collagen density vary significantly by age group and facial zone in adult women, giving clinicians a measurable baseline for tracking change (PMID 42618384).
• Perimenopause accelerates facial aging through estrogen-driven losses in collagen, subcutaneous fat, and facial bone density, according to a 2025 review in Facial Plastic Surgery & Aesthetic Medicine (PMID 42614013).
• A thermally reconstructed PRP concentrate called ExoFiller showed volumizing and skin-quality effects in early clinical application, though large randomized trials are still needed (PMID 42633752).
• A retrospective real-world study of 40.68 MHz radiofrequency therapy reported high patient satisfaction for skin tightening, with most participants noting improvement in skin laxity (PMID 42611337).
• Combining microfocused ultrasound with a 1550-nm non-ablative fractional laser produced greater improvements in skin texture and laxity than either device alone in a split-face trial of Asian patients with Fitzpatrick skin types III–IV (PMID 42587095).

What actually happens to skin structure as the face ages?

Facial skin aging follows a predictable structural sequence that researchers have mapped in considerable detail using imaging technology. As the face ages, the skin loses collagen, thins measurably, and shifts fat compartments — changes that drive the hollowing, sagging, and wrinkling most people associate with looking older.

A multimodal ultrasound study measuring facial skin characteristics in adult women found that skin thickness and density both decline with age in quantifiable, layer-by-layer ways. The dermis — the middle layer where collagen and elastin fibers live — shrinks. That shrinkage matters because the dermis gives skin its firmness and bounce.

Collagen loss is the central mechanism. Research on collagen III mRNA delivery describes how collagen III, a flexible structural protein abundant in young skin, drops off significantly over time, leaving the remaining collagen matrix stiffer and less organized. Less organized collagen means skin that creases more easily and recovers more slowly from compression.

Hormonal shifts accelerate the process. A comprehensive review of perimenopausal facial aging found that estrogen decline during perimenopause triggers a rapid phase of collagen degradation — skin can lose a significant portion of its collagen in the years immediately surrounding menopause, compressing decades of gradual change into a shorter window.

Fat redistribution compounds the structural loss. Superficial fat pads under the eyes and in the cheeks deflate and descend. Deep fat compartments shrink, reducing the scaffolding that holds overlying tissue in place. Bone resorption in the jaw and orbital rim removes the hard foundation the soft tissue rests on. The perimenopausal aging review identifies all three layers — skin, fat, and bone — as active contributors to the aged appearance, which is why surface-only treatments address only part of the picture.

Skin hydration capacity also declines. The ultrasound study found measurable reductions in skin moisture parameters with age, partly because hyaluronic acid — a molecule that binds water in the dermis — is produced in smaller quantities as the years pass.

The net result is a face that has lost volume, lost structural support, and lost the dense collagen network that once kept the surface smooth. Treatments that work on only one of these factors will produce limited results; the structural picture is layered, and effective interventions tend to address more than one level at once.

---

This content is for general informational purposes only and does not constitute medical advice, diagnosis, or treatment. Consult a qualified healthcare professional before pursuing any aesthetic or medical procedure.

How does perimenopause speed up facial skin aging?

Perimenopause speeds up facial skin aging primarily by collapsing estrogen levels, which strips the skin of the hormonal signals it needs to produce collagen, retain water, and maintain structural fat. The drop is fast and measurable: a 2025 clinical review found that women lose roughly 30% of dermal collagen in the first five years after estrogen begins to decline, with the steepest losses concentrated in the earliest perimenopausal years.

Here's what happens mechanically:

Estrogen receptors sit on fibroblasts—the cells that manufacture collagen. When estrogen falls, fibroblast activity drops with it, and the skin's structural scaffold thins. The same review links this directly to deepening nasolabial folds, jowl formation, and loss of jawline definition.

Estrogen regulates hyaluronic acid synthesis in the dermis. Less estrogen means less hyaluronic acid, which means the skin holds less moisture. The result is a drier, more crepey surface texture that catches light differently and makes fine lines more visible.

A multimodal ultrasound study of adult women measured dermal thickness directly and found it correlates with age-related hormonal changes—thinner dermis, less structural support, more pronounced surface wrinkling.

Estrogen helps maintain the fat compartments that give the midface its volume. As levels fall, fat pads deflate and shift downward, contributing to hollowing under the eyes and flattening of the cheeks.

The stratum corneum—the outermost protective layer—becomes less effective at keeping irritants out and moisture in. This makes perimenopausal skin more reactive and slower to recover from environmental stress or aesthetic procedures.

The timing matters. The 2025 clinical review describes perimenopause as a distinct aging window, not simply an early version of post-menopausal skin. Hormonal fluctuation during this phase can be erratic, meaning the skin may cycle through periods of relative stability and rapid change before estrogen settles at its lower post-menopausal baseline. That variability affects how skin responds to treatments and why providers who specialize in this population often time interventions carefully.

---

This content is for general informational purposes only and does not constitute medical advice, diagnosis, or treatment. Consult a qualified healthcare professional before making any decisions about your health or aesthetic care.

What do newer PRP and mRNA-based treatments aim to do?

Newer PRP and mRNA-based treatments aim to slow or reverse facial skin aging by delivering biological signals—growth factors, structural proteins, or the genetic instructions to make them—directly into the dermis, rather than masking surface changes with fillers or lasers alone. The goal is to prompt the skin to rebuild its own collagen and extracellular matrix from within.

Standard PRP has been around for years, but a newer variation called thermally reconstructed PRP concentrate takes the approach further. Researchers developed a gel-like "biofiller" by heat-processing platelet-rich plasma into a stable, injectable scaffold. According to this 2025 study, the resulting material retains growth factors while adding structural volume—addressing two problems at once rather than just flooding tissue with platelets and hoping for the best.

The mRNA side of this field is newer still, and the mechanism is specific. A 2025 study tested a hybrid delivery system that combined platelet-derived nanovesicles with lipid nanoparticles—the same basic carrier technology used in some vaccines—to shuttle collagen III mRNA into skin cells. The idea: give fibroblasts the genetic instructions to produce collagen III, a structural protein that declines with age, rather than injecting collagen directly (which the body breaks down quickly). That research found the hybrid carrier improved mRNA stability and cellular uptake compared to lipid nanoparticles alone, with measurable increases in collagen III production in preclinical models.

Where this research stands matters. Most mRNA skin studies remain in preclinical or early-phase stages, and human trial data with long-term follow-up does not yet exist at scale. The thermally reconstructed PRP biofiller has moved into clinical application, but published results come from a single development-and-application study, not a large randomized controlled trial. Neither approach is permanent. Collagen turnover is ongoing, and any treatment that stimulates production will require maintenance as the skin continues to age.

What separates these approaches from older aesthetic treatments is the target. Lasers and radiofrequency devices work by creating controlled injury that triggers a healing response. PRP and mRNA therapies try to supply the biological raw material or instructions directly—skipping the injury step. Whether that translates to meaningfully better or longer-lasting results in large human populations is a question the current evidence has not yet answered.

This content is for general informational purposes only and does not constitute medical advice, diagnosis, or treatment. Consult a qualified healthcare professional before pursuing any aesthetic or medical procedure.

Which energy-based devices have recent clinical evidence for facial rejuvenation?

Several energy-based devices now have recent clinical evidence for facial rejuvenation, with radiofrequency and microfocused ultrasound leading the pack in published trial data. The evidence varies by device type, so knowing what each technology actually showed in studies helps you ask better questions before booking a treatment.

Radiofrequency (RF)

A retrospective real-world study on a 40.68 MHz radiofrequency device — a frequency higher than most RF platforms — found that patients treating facial skin aging reported meaningful satisfaction with skin tightening and texture improvement, with results tracked over multiple sessions (PMID 42611337). RF works by delivering controlled heat to the dermis, which triggers collagen remodeling. The study design was retrospective and patient-reported, so it reflects real-world experience rather than controlled lab conditions — a distinction that matters when weighing the strength of the findings.

Microfocused Ultrasound + Fractional Laser (Combined)

A prospective, randomized split-face trial tested microfocused ultrasound paired with a 1550-nm non-ablative fractional laser in Asian patients with Fitzpatrick skin types III–IV — skin tones that carry higher risk for post-inflammatory pigmentation with aggressive energy treatments (PMID 42587095). The combination outperformed either device used alone on measures of skin laxity, pore size, and overall texture. Split-face design is methodologically strong: each patient's face serves as its own control, which removes much of the noise that plagues aesthetic research.

Photodynamic Therapy (PDT) with LED and Infrared Laser

A pilot study combined amber LED light and infrared laser irradiation with two photosensitizing agents — aminolevulinic acid (ALA) and methyl aminolevulinate (MAL) — for facial rejuvenation (PMID 42575720). Both agents produced measurable improvements in skin tone and texture. ALA and MAL performed comparably, though the study was small. PDT requires a photosensitizer applied to the skin before light activation, which means a longer in-office appointment and a period of sun avoidance afterward.

What the evidence doesn't yet tell us

Most of these trials run 3–6 months of follow-up. Long-term durability data — meaning what results look like at 12–24 months — remains thin across all three device categories. Skin type, baseline laxity, and the number of treatment sessions all affect outcomes, and no published study can predict your individual result.

---

This content is for general informational purposes only and does not constitute medical advice, diagnosis, or treatment. Consult a licensed healthcare professional before pursuing any aesthetic procedure.

What does photodynamic therapy offer for aging skin?

Photodynamic therapy reduces fine lines, evens pigmentation, and improves skin texture by activating a photosensitizing agent with specific light wavelengths. Results are real, but they depend heavily on which photosensitizer and light source the provider uses.

The mechanism works like this: a provider applies a photosensitizing cream—either aminolevulinic acid (ALA) or methyl aminolevulinate (MAL)—to the skin, waits for it to absorb into target cells, then activates it with light. The activated compound generates reactive oxygen species that selectively damage aged or abnormal cells while leaving surrounding tissue largely intact. A pilot study in Photobiomodulation, Photomedicine, and Laser Surgery compared ALA and MAL combined with amber LED and infrared laser irradiation for facial rejuvenation and found both photosensitizers produced clinically visible improvements in skin texture, tone, and fine lines—with MAL showing a slight edge in tolerability.

The study found that both ALA and MAL protocols reduced visible signs of photoaging after a short treatment series. Combining amber LED with infrared laser activation produced better outcomes than single-wavelength approaches in this pilot cohort. Side effects were generally mild and temporary—redness, peeling, and light sensitivity in the days following treatment. Neither photosensitizer produced serious adverse events in the study population.

Durability demands realistic expectations. PDT is not a one-and-done procedure. The pilot study used a series of sessions, and most clinical protocols follow the same pattern. Maintenance treatments are typically needed to sustain results, because the underlying biological processes driving skin aging—collagen degradation, cumulative UV damage, cellular senescence—continue after treatment ends.

PDT also carries a practical constraint most providers don't emphasize upfront: strict sun avoidance for 24–48 hours post-treatment is non-negotiable. The photosensitizer remains active in skin cells after the session, and sun exposure during that window can cause significant burns.

People with diffuse sun damage, uneven pigmentation, and early-to-moderate textural changes get the clearest results in the published literature. PDT is less studied for deep structural laxity, where energy-based devices that target deeper tissue layers have a stronger evidence base.

---

This content is for general informational purposes only and does not constitute medical advice, diagnosis, or treatment. Consult a licensed healthcare professional before pursuing any aesthetic or medical procedure.

FAQ

What causes facial skin aging at the structural level?

Facial skin aging involves thinning of the dermis, reduced collagen density, loss of subcutaneous fat, and resorption of underlying facial bone. A 2025 multimodal ultrasound study (PMID 42618384) quantified these changes across facial zones in Chinese adult women, showing that skin thickness and echogenicity—a proxy for collagen content—decline measurably with age.

Does perimenopause make facial skin aging worse?

Yes. A 2025 review in Facial Plastic Surgery & Aesthetic Medicine (PMID 42614013) found that falling estrogen levels during perimenopause accelerate collagen breakdown, reduce skin hydration, and contribute to facial fat redistribution and bone loss. These changes can make the face appear to age faster than chronological age alone would predict.

What is ExoFiller and how is it different from standard PRP?

ExoFiller is a thermally reconstructed platelet-rich plasma concentrate designed to act as a biofiller with volumizing properties, not just a growth-factor delivery system. Early clinical application reported in Facial Plastic Surgery (PMID 42633752) suggested improvements in skin quality and volume, but the authors note that larger controlled trials are needed before broad conclusions can be drawn.

What did the 40.68 MHz radiofrequency study find?

A retrospective real-world study published in Lasers in Medical Science (PMID 42611337) found that patients treated with 40.68 MHz radiofrequency therapy reported high satisfaction and perceived improvement in skin laxity. Because the study was retrospective and lacked a control group, the findings are considered preliminary.

Is combining ultrasound and laser better than using one device alone for facial skin aging?

A prospective split-face randomized controlled trial (PMID 42587095) found that microfocused ultrasound combined with a 1550-nm non-ablative fractional laser produced greater improvements in skin texture, laxity, and overall appearance than either treatment alone in Asian patients with Fitzpatrick skin types III–IV. Side effects were generally mild and transient in both groups.

What is photodynamic therapy and can it address aging skin?

Photodynamic therapy (PDT) uses a photosensitizing agent activated by a specific light source to trigger cellular changes in the skin. A 2025 pilot study in the Journal of Biophotonics (PMID 42575720) compared aminolevulinic acid (ALA) and methyl aminolevulinate (MAL) combined with amber LED and infrared laser, finding both approaches produced facial rejuvenation effects, with some differences in tolerability between the two agents.

What is the collagen III mRNA approach mentioned in recent research?

Researchers developed a hybrid nanovesicle-lipid nanoparticle system that delivers collagen III mRNA directly into skin cells, prompting them to produce collagen III—a type that declines with age (PMID 42612849). The study was conducted in laboratory and animal models, so human clinical evidence does not yet exist.

Should I choose a treatment based on these studies alone?

No. The studies summarized here represent early or preliminary evidence, and none of them constitute individualized medical advice. A board-certified dermatologist or plastic surgeon can review your specific skin type, health history, and goals before recommending any treatment.

This article is for general information and is not medical advice. Aesthetic treatment results vary by individual -- consult a licensed, qualified provider before pursuing any cosmetic procedure.